This trial is active, not recruiting.

Condition solid neoplasm
Treatments erlotinib hydrochloride, laboratory biomarker analysis, pharmacological study, tipifarnib
Phase phase 1
Target EGFR
Sponsor National Cancer Institute (NCI)
Start date May 2004
End date May 2008
Trial size 29 participants
Trial identifier NCT00085553, 6014, CDR0000370818, MAYO-MC0212, MC0212, NCI-2012-02597, NCI-6014, P30CA015083, U01CA069912


This phase I trial studies the side effects and best dose of tipifarnib and erlotinib hydrochloride in treating patients with solid tumors that have spread to other places in the body. Tipifarnib and erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Patients receive erlotinib hydrochloride PO QD on days 1-28 (days 8-28 of course 1 as of 11/4/2013) and tipifarnib PO BID on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. (Closed to accrual as of 2/2/06)
erlotinib hydrochloride Cp-358,774
Given PO
laboratory biomarker analysis
Correlative studies
pharmacological study
Correlative studies
tipifarnib R115777
Given PO

Primary Outcomes

Incidence of all adverse events, graded according to the National Cancer Institute Common (NCI) Terminology Criteria for Adverse Events (CTCAE) version 3.0
time frame: Up to 30 days after last study treatment
Incidence of toxicity graded according to NCI CTCAE version 3.0
time frame: Up to 3 months

Secondary Outcomes

Best response as assessed by the Response Evaluation Criteria in Solid Tumors
time frame: Start of the treatment until disease progression/recurrence, assessed up to 3 months
Time to progression
time frame: Up to 3 months
Time to treatment failure
time frame: Time from registration to documentation of progression, unacceptable toxicity, or refusal to continue participation by the patient, assessed up to 3 months
Time until any treatment related toxicity
time frame: Up to 30 days after last study treatment
Time until hematologic nadirs (white blood cells, ANC, platelets)
time frame: Up to 3 months
Time until treatment related grade 3+ toxicity
time frame: Up to 30 days after last study treatment

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Histologic proof of cancer that is unresectable and for which no standard life-prolonging therapy is available - Absolute neutrophil count (ANC) >= 1500/uL - Platelet count (PLT) >= 100,000/uL - Total bilirubin =< 2 mg/dL - Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN) - Creatinine =< 1.5 x ULN - Hemoglobin (Hgb) >= 9.0 g/dL - Ability to provide informed consent - Willingness to return to Mayo Clinic Rochester for follow up - Life expectancy >= 12 weeks - At maximum tolerated dose (MTD) only: tumor that is amenable for serial biopsy - Medically capable and willing to provide the biologic specimens as required by the protocol Note: The goals of this study include assessment of the biologic effects on surrogate markers of the agent(s) being tested and are, therefore, contingent upon availability of the biologic specimens; patients with pre-existing clinical contraindications (e.g. anticoagulant therapy) for biopsy will be excluded from participation in the study; however, those patients who develop a major complication associated with the first biopsy (e.g. bleeding) or who develop clinical contraindications (e.g., anticoagulant therapy) after entry on study may remain on the study without the requirement for further tissue biopsies; this stipulation only applies to the 12 patients enrolled in Cohort II at MTD; the stipulation for provision of biologic specimens, as noted above, excludes the optional pharmacogenomic specimen Exclusion Criteria: - Known standard therapy for the patient's disease that is potentially curative or definitely capable of extending life expectancy - Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2, 3, or 4 - Uncontrolled infection - Any of the following prior therapies: - Chemotherapy =< 4 weeks prior to study entry - Mitomycin C/nitrosoureas =< 6 weeks prior to study entry - Immunotherapy =< 4 weeks prior to study entry - Biologic therapy =< 4 weeks prior to study entry - Hormonal cancer therapy =< 4 weeks prior to study entry - Radiation therapy =< 4 weeks prior to study entry - Radiation to > 25% of bone marrow - Failure to fully recover from acute, reversible effects of prior chemotherapy regardless of interval since last treatment - New York Heart Association classification III or IV - Patients on enzyme-inducing anticonvulsants (Phenobarbital, Dilantin, or Tegretol) - Any of the following: - Pregnant women - Nursing women - Men or women of childbearing potential who are unwilling to employ adequate contraception (condoms plus spermicidal agents, diaphragm, birth control pills, injections, intrauterine device [IUD], or abstinence, etc.) - Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational (utilized for a non-Food and Drug Administration [FDA]-approved indication and in the context of a research investigation) - Uncontrolled intercurrent illness including, but not limited to: - Ongoing or active infection - Symptomatic congestive heart failure - Unstable angina pectoris - Cardiac arrhythmia - Psychiatric illness/social situations that would limit compliance with study requirements - Prior treatment with EGFR targeting therapies (e.g., ZD-1869, EKB-569, OSI-774, CI-1033, GW572016, C225, EMD72000) or Farnesyl transferase inhibitors (R115777, SCH66336, BMS2146632) - Major surgery, or significant traumatic injury occurring =< 21 days prior to study entry - Abnormalities of the cornea based on history (e.g., dry eye syndrome, Sjögren's syndrome), congenital abnormality (e.g., Fuch's dystrophy), abnormal slit-lamp examination using a vital dye (e.g., fluorescein, Bengal-Rose), and/or an abnormal corneal sensitivity test (Schirmer test or similar tear production test) - Gastrointestinal tract disease resulting in an inability to take oral or nasogastric medication or a requirement for intravenous (IV) alimentation, prior surgical procedures affecting absorption, or active peptic ulcer disease - Human immunodeficiency virus (HIV)-positive patients receiving combination anti-retroviral therapy - Known brain metastases unless treated with surgery and/or radiation and stable for >= 8 weeks; patient should not be on enzyme-inducing anticonvulsants (Phenobarbital, Phenytoin (Dilantin) or Carbamazepine (Tegretol))

Additional Information

Official title Phase I Trial of R115777 and OSI-774 in Patients With Advanced Solid Tumors
Principal investigator Julian Molina
Description PRIMARY OBJECTIVES: I. To determine the maximal tolerated dose of R115777 (tipifarnib) in combination with OSI-774 (erlotinib hydrochloride). II. To describe the toxicity profile of this combination. III. To evaluate the effect of OSI-774 on the disposition of R115777. IV. To evaluate in vitro markers of farnesyl transferase (FT) inhibition and epidermal growth factor receptor (EGFR) inhibition. OUTLINE: This is a dose-escalation study. Patients receive erlotinib hydrochloride orally (PO) once daily (QD) on days 1-28 (days 8-28 of course 1 as of 11/4/2013) and tipifarnib PO twice daily (BID) on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. (Closed to accrual as of 2/2/06) After completion of study treatment, patients are followed up at 3 months.
Trial information was received from ClinicalTrials.gov and was last updated in December 2016.
Information provided to ClinicalTrials.gov by National Cancer Institute (NCI).